Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TAEST16001 in NY-ESO-1-positive HLA-A*02:01-positive advanced soft tissue sarcoma
CTR20221312Phase 2Active
- Sponsor
- Xiangxue Precision Medical Technology
- Start
- Nov 2022
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of TAEST16001 in soft tissue sarcoma (STS), sponsored by Xiangxue Precision Medical Technology. Started Nov 2022; status: active.
02
Drugs
TAEST16001
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20221312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221312.